Problematic issues of autoimmune hepatitis in children


  • O.Yu. Belousova Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine
  • O.M. Babadzhanyan Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine



autoimmune hepatitis, children, diagnosis


Recently, autoimmune hepatitis (AIH) is beco-ming more common; as stated in the EASL 2015 recommendation, it can occur in any population and in all age groups. The etiology of AIH is unknown, the pathogenesis is insufficiently studied. Factors that directly trigger the autoimmune process have not been established. They can belong to environmental and infectious agents. Autoimmune hepatitis is heterogeneous in both clinical and serological manifestations, is characterized by a wide range of clinical symptoms of the disease: from asymptomatic to severe course, with or without extrahepatic manifestations, which can affect almost all organs and systems. AIH has a variety of clinical manifestations, it is not a clinically stable process, it should be excluded in all patients with symptoms of liver damage. Own observations of children with AIH with atypical manifestations of the disease are presented. Positive autoantibodies and the use of a pediatric scale are the keys in AIH diagnosis. With the exception of the fulminant course of the disease, AIH responds well to immunosuppressive therapy regardless of the degree of liver dysfunction. In childhood, remission is achieved in 60–90 % of patients depending on the severity of the disease at its manifestation, speed and degree of response to treatment.


European Association for the Study of the Liver. EASL clinical practice guidelines: autoimmune hepatitis. J. Hepatol. 2015. 63(4). 971­1004. DOI: 10.1016/j.jhep.2015.06.030.

Jiménez­Rivera C., Ling S.C., Ahmed N., Yap J., Aglipay M., Barrowman N. et al. Incidence and Characteristics of Autoimmune Hepatitis Pediatrics. 2015. 136(5). e1237­48. DOI: 10.1542/peds.2015­0578.

Mieli­Vergani G., Vergani D. Budesonide for juvenile auto­ immune hepatitis? Not yet. J. Pediatr. 2013. 163(5). 1246­8. DOI: 10.1016/j.jpeds.2013.06.064.

Gronbaek L., Vilstrup H., Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry­based cohort study. J. Hepatol. 2014. 60(3). 612­7. DOI: 10.1016/j. jhep.2013.10.020.

Ramachandran J., Sajith K.G., Pal S., Rasak J.V., Prakash J.A., Ramakrishna B. Clinicopathological profile and management of severe autoimmune hepatitis. Trop. Gastroenterol. 2014. 35. 25­31. PMID: 25276903.

Di Giorgio A., Bravi M., Bonanomi E., Alessio G., Sonzogni A., Zen Y., Colledan M., D’Antiga L. Fulminant hepatic failure of autoimmune aetiology in children. J. Pediatr. Gastroenterol. Nutr. 2015. 60(2). 159­64. DOI 10.1097/MPG.0000000000000593.

Anania C., De Luca E., De Castro G., Chiesa C., Pacifico L. Liver involvement in pediatric celiac disease. World J. Gastroenterol. 2015. 21(19). 5813­22. DOI: 10.3748/ wjg.v21.i19.5813.

de Boer Y.S., van Nieuwkerk C.M., Witte B.I., Mulder C.J., Bouma G., Bloemena E. Assessment of the histopatholo­gical key features in autoimmune hepatitis. Histopathology. 2015. 66(3). 351­62. DOI: 10.1111/his.12558.

Miao Q., Bian Z., Tang R., Zhang H., Wang Q., Huang S., Xiao X., Shen L., Qiu D., Krawitt E.L., Gershwin M.E., Ma X. Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis. Clin. Rev. Allergy Immunol. 2015. 48(2–3). 226­35. DOI 10.1007/s12016­014­8432­0.

Tucker S.M., Jonas M.M., Perez­Atayde A.R. Hyaline droplets in Kupffer cells: a novel diagnostic clue for autoimmune hepatitis. Am. J. Surg. Pathol. 2015. 39(6). 772­8. DOI: 10.1097/PAS.0000000000000395.

Villalta D., Girolami E., Alessio M.G. et al. Autoantibody Profiling in a Cohort of Pediatric and Adult Patients With Autoimmune Hepatitis. J. Clin. Lab. Anal. 2016. 30. 41.

Mieli­Vergani G., Vergani D., Baumann U., Czubkow­ski P., Debray D., Dezsofi A. et al. Diagnosis and Management of Pediatric Autoimmune Liver Disease: ESPGHAN Hepatology Committee Position Statement. Journal of Pediatric Gastroenterology and Nutrition. 2018 Feb. 66(2). 1. Р. 345­360. DOI: 10.1097/MPG.0000000000001801.

Mackay I.R. Autoimmune hepatitis: what must be said. Exp. Mol. Pathol. 2012. Vol. 93. P. 350­353.

Gregorio G.V., McFarlane B., Bracken P., Vergani D., Mieli­Vergani G. Organ and non­organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity. 2002. 35. 515­519.

Anand L., Choudhury A., Bihari C. et al. Flare of Autoimmune Hepatitis Causing Acute on Chronic Liver Failure: Diagnosis and Response to Corticosteroid Therapy. Hepatology. 2019. 70. 587.

Mack C.L., Adams D., Assis D.N. et al. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020. 72. 671.

Van Gerven N.M., de Boer Y.S., Mulder C.J., van Nieuwkerk C.M. et al. Autoimmune hepatitis. World J. Gastroenterol. 2016. Vol. 22. № 19. P. 4651­4661.

Wang Q., Yang F., Miao Q. et al. The clinical phenotypes of autoimmune hepatitis: A comprehensive review. J. Autoimmun. 2016. 66. 98.

Manns M.P., Lohse A.W., Vergani D. Autoimmune hepatitis — Update 2015. J. Hepatol. 2015. 62. S100.

Liberal R., Grant C.R. Cirrhosis and autoimmune liver disease: current understanding. World J. Hepatol. 2016. 8(28). 1157­68. DOI: 10.4254/wjh.v8.i28.1157.

D’Agostino D., Costaguta A., Alvarez F. Successful treatment of refractory autoimmune hepatitis with rituximab. Pediatrics. 2013. 132. e526­30. DOI: 10.1542/peds.2011­1900.

Floreani A., Libera R., Vergani D., Mieli­Vergani G. Autoimmune hepatitis: contrasts and comparisons in children and adults — a comprehensive review. J. Autoimmun. 2013. 46. 7­16. DOI: 10.1016/j.jaut.2013.08.004.

Kumari N., Kathuria R., Srivastav A., Krishnani N., Podda U., Yachha S.K. Significance of histopathological features in differentiating autoimmune liver disease from nonautoimmune chronic liver disease in children. Eur. J. Gastroenterol Hepatol. 2013. 25. 333­7. DOI: 10.1097/MEG.0b013e32835a68a1.

Czaja A.J. Nonstandard drugs and feasible new interventions for autoimmune hepatitis: part I. Inflamm. Allergy Drug Targets. 2012. 11(5). 337­50.

de Boer Y.S., Gerussi A., van den Brand F.F. et al. Association Between Black Race and Presentation and Liver­Related Outcomes of Patients With Autoimmune Hepatitis. Clin. Gastroenterol. Hepatol. 2019. 17. 1616.

Kerkar N., Czaja A.J., Mack C.L., Adams D., Assis D.N., Manns M.P., Mayo M.J., Nayfeh T., Majzoub A.M.M. Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta­Analyses Supporting American Association for the Study of Liver Diseases Guidelines Hepatology. 2020. Vol. 72. Іssue 2. Р. 753­769.

Noguchi F., Chu P.­S., Taniki N., Yoshida A., Morikawa R., Yamaguchi A., Ikura A., Yamataka К., Hoshi H., Usui Sh., Ebinuma H., Saito H., Kanai T., Nakamoto N. Long­term Observation of Cyclosporine as Second­line Therapy in Adults of Severe Acute Autoimmune Hepatitis. 17 October 2020. Wiley Online Library.





To Help the Practitioner